Foundayo Guide
Foundayo (orforglipron) was the first small-molecule GLP-1 receptor agonist to win FDA approval in an oral once-daily form for chronic weight management. That approval landed on April 1, 2026. One tablet a day with no food or water restrictions, marking a major change from injectable GLP-1s and from oral semaglutide (Rybelsus), which has strict food and water rules. In the 72-week ATTAIN-1 phase 3 trial, the highest dose produced 12.4% mean weight loss versus 0.9% on placebo.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
At a Glance
| Generic Name | Orforglipron |
| Brand Names | Foundayo |
| FDA Status | FDA-approved for chronic weight management in adults with obesity, or overweight with weight-related medical problems, alongside a reduced-calorie diet and increased physical activity (April 1, 2026). Not approved for pediatric use. Cannot be used with other GLP-1 receptor agonists.[1] |
| Approval Date | April 1, 2026[1] |
How Foundayo Works
Orforglipron is not built as a peptide. It is a small organic molecule that binds the GLP-1 receptor and switches it on directly. Unlike injectable GLP-1 peptides (semaglutide, tirzepatide) or oral peptide formulations (Rybelsus), orforglipron is a true small organic molecule that survives stomach acid and digestion, eliminating the need for injection or special food restrictions. It produces the same downstream effects as injectable GLP-1 agonists: appetite suppression, slowed gastric emptying, and reduced food reward signaling.[2]
Dosing Schedule
Foundayo uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].
Side Effects
Common: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, swollen belly, fatigue, belching, heartburn, gas, hair loss. Serious: pancreatitis, dehydration leading to kidney problems, gallbladder disease, hypoglycemia (especially with insulin/sulfonylureas), serious allergic reactions, diabetic retinopathy progression in T2D patients, increased aspiration risk during anesthesia. Boxed warning: thyroid C-cell tumors observed in animal studies. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).[1][2]
Nothing above is the full list. Your prescriber can give you the complete safety picture, and every adverse reaction on record sits in the current FDA prescribing information[1].
Clinical Trial Results
ATTAIN-1 (NCT05869903) ran its full 72-week course across 10 countries: phase 3, randomized, placebo-controlled, 3,127 adults, all of them obese or overweight carrying a weight-related comorbidity, none of them diabetic. Highest dose produced 12.4% mean body weight reduction (~27 lbs) versus 0.9% on placebo (efficacy estimand). Treatment-regimen estimand: 11.1% (~25 lbs) vs 2.1% placebo. Every dose also moved four secondary measures: systolic blood pressure, triglycerides, non-HDL cholesterol and waist circumference all fell. ATTAIN-2 in patients with type 2 diabetes is ongoing.[2]
Where to Get Foundayo
Sellers in our register that will dispense orforglipron, or a compounded version of it, after an online consultation — shipped to your door.
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Cost Comparison
What each seller in the register charges to start on a compounded GLP-1, cheapest at the top. Compounded orforglipron from licensed 503A and 503B pharmacies is legal under federal compounding law[3], and the rules have historically loosened further for any molecule sitting on the FDA Drug Shortage List[4]. An FSA or HSA will generally cover either kind of prescription, compounded or branded, under IRS Publication 502[5]. What you actually pay moves with your dose and with whatever promotion happens to be running.
| Provider | Starting Price | Link | |
|---|---|---|---|
| Amazon One Medical | brand | $149/mo | Visit |
| GoodRx | brand | $149/mo | Visit |
| Kin Meds | brand | $149/mo | Visit |
| LillyDirect Foundayo | brand | $149/mo | Visit |
| PreventiveMD | brand | $149/mo | Visit |
| Ro | brand | $149/mo | Visit |
Foundayo Head-to-Head Comparisons
Short verdict pages setting Foundayo against the other GLP-1 options, working from the trial results, the dose ladders on each label, and what the manufacturers charge today.
See all drug-vs-drug verdicts.
Foundayo Patient Questions, Answered
Questions people actually asked about Foundayo in named subreddits, each answered from the published trial data.
Foundayo Reference Cards
One-screen references for the dose schedule, what to do about a missed dose, and the side effects that warrant a call. Every figure checked against the DailyMed label.
Related Research on Foundayo
Longer pieces written here, built on the trial papers themselves, checked against the FDA label, and argued rather than summarized.
Frequently Asked Questions
Sources & methodology — as of September 2026
- 1.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 2.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 3.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 4.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 5.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.
Glossary
The words sellers use, defined. Tap any term.
- Orforglipron · Drugs and brands
- Wegovy · Drugs and brands
- Zepbound · Drugs and brands
- GLP-1 receptor · Mechanism